139 related articles for article (PubMed ID: 33378376)
1. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
Cullum RL; Lucas LM; Senfeld JI; Piazza JT; Neel LT; Whig K; Zhai L; Harris MH; Rael CC; Taylor DC; Cook LJ; Kaufmann DP; Mill CP; Jacobi MA; Smith FT; Suto M; Bostwick R; Gupta RB; David AE; Riese Ii DJ
PLoS One; 2020; 15(12):e0243901. PubMed ID: 33378376
[TBL] [Abstract][Full Text] [Related]
2. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
[TBL] [Abstract][Full Text] [Related]
3. Inter-conversion of neuregulin2 full and partial agonists for ErbB4.
Wilson KJ; Mill CP; Cameron EM; Hobbs SS; Hammer RP; Riese DJ
Biochem Biophys Res Commun; 2007 Dec; 364(2):351-7. PubMed ID: 17945187
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
[TBL] [Abstract][Full Text] [Related]
5. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.
Hobbs SS; Cameron EM; Hammer RP; Le AT; Gallo RM; Blommel EN; Coffing SL; Chang H; Riese DJ
Oncogene; 2004 Jan; 23(4):883-93. PubMed ID: 14661053
[TBL] [Abstract][Full Text] [Related]
6. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
7. ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway.
Xu J; Gong L; Qian Z; Song G; Liu J
Oncol Rep; 2018 Jun; 39(6):2892-2898. PubMed ID: 29620274
[TBL] [Abstract][Full Text] [Related]
8. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner.
Rauf F; Festa F; Park JG; Magee M; Eaton S; Rinaldi C; Betanzos CM; Gonzalez-Malerva L; LaBaer J
Oncogene; 2018 Apr; 37(17):2237-2250. PubMed ID: 29398709
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.
Gallo RM; Bryant I; Fry R; Williams EE; Riese DJ
Biochem Biophys Res Commun; 2006 Oct; 349(1):372-82. PubMed ID: 16934755
[TBL] [Abstract][Full Text] [Related]
11. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.
Mill CP; Zordan MD; Rothenberg SM; Settleman J; Leary JF; Riese DJ
Genes Cancer; 2011 Aug; 2(8):792-804. PubMed ID: 22393464
[TBL] [Abstract][Full Text] [Related]
12. Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation.
Haryuni RD; Watabe S; Yamaguchi A; Fukushi Y; Tanaka T; Kawasaki Y; Zhou Y; Yokoyama S; Sakurai H
Biochem Biophys Res Commun; 2019 Jun; 514(2):456-461. PubMed ID: 31053301
[TBL] [Abstract][Full Text] [Related]
13. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
Gordon-Thomson C; Jones J; Mason RS; Moore GP
Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new erbB4 inhibitors: Repositioning an orphan chemical library by inverse virtual screening.
Giordano A; Forte G; Massimo L; Riccio R; Bifulco G; Di Micco S
Eur J Med Chem; 2018 May; 152():253-263. PubMed ID: 29730188
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
16. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.
Streets AJ; Magayr TA; Huang L; Vergoz L; Rossetti S; Simms RJ; Harris PC; Peters DJ; Ong AC
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F577-F588. PubMed ID: 28077374
[TBL] [Abstract][Full Text] [Related]
17. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*.
Hobbs SS; Gallo RM; Riese DJ
Growth Factors; 2005 Dec; 23(4):273-83. PubMed ID: 16338790
[TBL] [Abstract][Full Text] [Related]
18. ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migration.
Gambarotta G; Garzotto D; Destro E; Mautino B; Giampietro C; Cutrupi S; Dati C; Cattaneo E; Fasolo A; Perroteau I
J Biol Chem; 2004 Nov; 279(47):48808-16. PubMed ID: 15355992
[TBL] [Abstract][Full Text] [Related]
19. ErbB4-mediated regulation of vasculogenic mimicry capability in breast cancer cells.
Kawahara R; Simizu S
Cancer Sci; 2022 Mar; 113(3):950-959. PubMed ID: 34971015
[TBL] [Abstract][Full Text] [Related]
20. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
Haskins JW; Nguyen DX; Stern DF
Sci Signal; 2014 Dec; 7(355):ra116. PubMed ID: 25492965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
